How can genetic variations affect drug effectiveness, using Codeine as an example?

Codeine is converted to morphine by the CYP2D6 enzyme. About 7% of Caucasians have a gene variation that makes CYP2D6 inactive, meaning Codeine has no pain-relieving effect for them, acting like a placebo.

What are Single Nucleotide Polymorphisms (SNPs)?

SNPs are the most common type of genetic variation, representing a difference in a single DNA building block (base) at a specific position in the genome. These variations can influence observable traits and responses, such as how a person reacts to a medication.

What is the purpose of the PharmGKB database?

PharmGKB (Pharmacogenomics Knowledge Base) is a public repository designed to support pharmacogenomics research. It curates and provides access to high-quality data linking genetic variations (genotypes) with measurable biological and clinical characteristics (phenotypes), as well as information on drug metabolism and pathways.

What are the main challenges in implementing pharmacogenomics in routine clinical practice?

Key challenges include the cost and quality control of genetic testing, ethical issues surrounding data privacy and security, and the lack of a robust health information infrastructure to deliver genetic insights to clinicians within short patient appointment times.

Can genetic data be used to re-identify individuals, even if de-identified?

Yes, there is a risk. Even with de-identified genetic data, combining it with other public or private databases (like voter or DMV records) can potentially re-identify individuals or narrow down possibilities significantly, posing a concern for privacy.

Are there opportunities for collaboration between organizations like FDA, PharmGKB, and Google in pharmacogenomics?

The speaker suggests potential partnerships to improve the tracking of adverse drug events, leverage search engine capabilities for data analysis, and accelerate research by integrating disparate data sources and improving accessibility.

Why is understanding genotype-phenotype relationships crucial for medicine?

Understanding these relationships allows for better predictions of disease risk, prognosis, diagnosis, and treatment response. By linking genetic information to observable traits, clinicians can make more informed decisions about patient care, moving towards truly genome-informed medicine.

Key Moments

Opportunities For Pharmacogenomics and Personalized Medicine

Google Talks

Education5 min read53 min video

Aug 22, 2012|1,278 views|7

googlevideo

Save to Pod

Key Moments

TL;DR

Pharmacogenomics uses genetic data for personalized medicine to improve drug efficacy and safety.

Key Insights

Human genetic variation (around 0.3%) significantly impacts individual responses to medications.

Pharmacogenomics aims to link genotype (DNA sequence) to phenotype (observable traits like drug response) for personalized treatment.

Variations in genes like CYP2D6 affect drug metabolism, making some common drugs ineffective for certain populations (e.g., codeine).

Drug trials may initially show no overall benefit but can reveal ethnic-specific efficacy, leading to targeted approvals (e.g., BiDil).

Databases like PharmGKB are crucial for collecting, curating, and disseminating genotype and phenotype data.

Challenges remain in data integration, cost reduction, ethical considerations, and healthcare infrastructure for widespread adoption.

UNDERSTANDING HUMAN GENETIC DIVERSITY

The human genome, composed of three billion DNA bases, is largely uniform across individuals (99.7%). However, the remaining 0.3% of variation, along with environmental factors, accounts for significant differences in traits and responses. Approximately one million positions in the genome vary across humans at a significant frequency, leading to a vast potential for diversity in human genomes. Characterizing these variations, known as genotypes, is key to understanding individual differences.

CONNECTING GENOTYPE TO PHENOTYPE

The core of personalized medicine lies in understanding the relationship between an individual's genotype and their phenotypes, which are any measurable characteristics not determined by DNA sequence. This includes susceptibility to diseases or the likelihood of responding effectively to specific medications. While statistical correlations can predict outcomes, a deeper mechanistic understanding of how genetic variations lead to cellular changes and observable phenotypes is also a significant area of research.

PHARMACOGENOMICS: TAILORING DRUG RESPONSES

Pharmacogenomics studies how genetic variations influence drug responses. For instance, variations in the CYP2D6 enzyme can render codeine ineffective for up to 7% of Caucasians, as their bodies cannot convert it to active morphine. This highlights the potential for personalized medicine to improve drug efficacy by identifying individuals who will benefit from a medication and avoid those who won't respond or may experience adverse reactions.

CASE STUDIES IN PERSONALIZED DRUG USE

The drug BiDil, used for heart failure, initially showed no overall benefit in general population trials. However, further analysis revealed significant efficacy in patients of African descent. This led to its FDA approval for this specific group, although the genetic basis for this response is still being investigated, with skin color currently serving as a proxy. This illustrates how genetic insights can revive drugs initially deemed ineffective for broad use.

THE ROLE OF PHARMGKB DATABASE

PharmGKB is a crucial public repository that collects and curates pharmacogenomic data, linking genotype information with clinical and laboratory phenotypes. Its mission is to create a national data resource with high-quality, integrated data, including genotype, phenotype, pathways, and annotated literature. The database aims to facilitate research by providing access to de-identified datasets, enabling users to explore relationships between genetic variations and drug responses.

CHALLENGES AND FUTURE OPPORTUNITIES

Widespread adoption of pharmacogenomics faces several challenges. These include reducing genotyping costs, ensuring data quality and security, navigating complex ethical issues surrounding genetic data privacy, and developing robust healthcare information infrastructures for seamless integration into clinical practice. Overcoming these hurdles is essential for realizing the full potential of personalized medicine, which promises to improve drug efficacy, reduce adverse events, and enhance patient outcomes.

DATA QUALITY AND SCIENTIFIC DISCOVERY

The quality of data in pharmacogenomics is paramount. While genotype data undergoes rigorous validation, phenotype data is more challenging due to varied measurement methods. The peer-review process and inter-laboratory concordance serve as critical quality control mechanisms. The increasing availability of genomic data, coupled with advanced informatics tools, fuels a growing number of research possibilities, enabling discoveries without requiring extensive wet lab work.

PRIVACY AND IDENTIFICATION RISKS

A significant concern in genetic databases is the potential for re-identification, even with de-identified data. As few as 60-100 specific genetic variations can uniquely identify an individual. This risk necessitates strict protocols for data access, including user registration, usage policies, and audit trails, to safeguard patient privacy and prevent misuse of sensitive genetic information, which could have implications for insurance or employment.

ADVANCEMENTS IN GENOMIC TECHNOLOGY

Technological advancements are rapidly reducing the cost and increasing the throughput of genomic sequencing and genotyping. This shift is enabling researchers to move from analyzing individual genetic variations to examining entire genomes comprehensively. Databases like PharmGKB are adapting to accommodate this influx of data, developing capabilities for chromosome-level browsing and managing vast amounts of genetic information per individual.

DRUG ADVERSE EVENTS AND DATA PARTNERSHIPS

Tracking drug adverse events (ADRs) is a critical area. The FDA's adverse event reporting system collects a substantial number of reports, but underestimation is likely due to reporting burdens. Potential partnerships between entities like the FDA, PharmGKB, and Google could significantly improve the capture and analysis of ADR data, potentially accelerating the identification of drug-related risks and informing better prescribing practices.

SCIENTIFIC LITERATURE MINING AND DATA INTEGRATION

Machine learning algorithms are being employed to efficiently scan vast medical literature for relevant pharmacogenomic articles, aiding curators in identifying and annotating key research. This systematic approach to data mining, along with the integration of diverse biological data types like gene expression, is essential for building a comprehensive understanding of drug-gene interactions and developing new therapeutic strategies.

THE FUTURE VISION: UNIVERSAL PERSONALIZED MEDICINE

The ultimate goal of pharmacogenomics is to enable optimal medical decision-making for all individuals worldwide, leveraging their unique genetic profiles. This vision requires a global healthcare system where genotypes are integrated responsibly into patient records, accessible for clinical decision-making. The development of secure, patient-controlled data systems and widespread agreement on data governance are key to achieving truly personalized and preventative healthcare on a global scale.

Mentioned in This Episode

●Software & Apps

●Companies

●Organizations

●Drugs & Medications

●Concepts

●People Referenced

Pharmacogenomics and Personalized Medicine: Key Takeaways

Practical takeaways from this episode

Do This

Understand that genetic variation (SNPs) accounts for individual differences in drug response.

Consider pharmacogenomics to predict drug efficacy and avoid adverse reactions.

Utilize resources like PharmGKB for curated genotype-phenotype data and research insights.

Be aware of the potential for re-identification with genetic data and advocate for responsible data handling.

Recognize that non-coding DNA ('junk DNA') can also contain significant variations.

Support the development of robust health information infrastructure for integrating genomic data into clinical practice.

Avoid This

Assume a 'one-size-fits-all' approach to medication is always effective.

Ignore the statistical relationship between genotype and phenotype, even without a full mechanistic understanding.

Underestimate the importance of environmental factors in conjunction with genetics in determining health outcomes.

Disregard the ethical implications of genetic data privacy and security.

Assume rare diseases or unique genetic variations are not linked to important phenotypes.

Common Questions

Pharmacogenomics studies how genetic variations influence an individual's response to drugs. It's a key component of personalized medicine, aiming to tailor medical treatment, including drug selection and dosage, based on a patient's unique genetic makeup.

Topics

Health & Longevity Technology & Innovation Science & Mathematics Data Privacy Personalized Medicine Genetic Variation Genomic Data Drug Response Biomedical Informatics

Mentioned in this video

Organizations

Stanford University

The institution where Professor Russ Altman works as a professor of genetics and medicine, and directs the biomedical informatics program.

Human Genome Project

The initiative that successfully sequenced the average human genome, making it of interest to understand individual genetic variations.

FDA

The Food and Drug Administration, responsible for approving drugs based on statistical evidence of efficacy and monitoring adverse events.

National Institutes of Health

Funded the development of the Pharmacogenomics Knowledge Base (PharmGKB) as a public resource for pharmacogenomic research.

U.S. Food and Drug Administration

Charged with tracking adverse drug events through its Adverse Event Reporting System (AERS).

National Cancer Institute

Runs the Cancer Genome Project, which sequences the genomes of cancerous cells from humans.

People

Russ Altman

Professor of genetics and medicine at Stanford University, director of the biomedical informatics program, and principal investigator for the PharmGKB.

Companies

Google

Mentioned as the platform for public availability of the video and for its data growth curves, and as a potential partner for health information infrastructure.

Concepts

Out of Africa hypothesis

A theory explaining human genetic diversity originating from a small ancestral population migrating out of Africa.

Single Nucleotide Polymorphism

A variation at a single position in a DNA sequence among individuals, fundamental to understanding genetic differences.

pharmacogenomics

The study of how an individual's genetic makeup affects their response to drugs, forming the basis of personalized medicine.

Pharmacogenetics

The study of how genetic variation influences drug response, closely related to pharmacogenomics.

Adverse Drug Reaction

An adverse event caused by taking a drug, with common types including heart arrhythmias, liver responses, and dermatological rashes.

Drugs & Medications

Codeine

A pain medication that requires activation by the CYP2D6 enzyme in the liver to become effective morphine.

BiDil

A combination drug initially showing no overall benefit for heart disease but later approved for African descent patients based on subgroup analysis.

Software & Apps

PharmGKB

The Pharmacogenomics Knowledge Base, a public repository of genotype and phenotype data, pathways, and literature curated to support pharmacogenomic research.

GenBank

A successful biological database holding raw DNA sequence data, serving as a benchmark for user traffic in biological databases.

Cancer Genome Project

A project by the National Cancer Institute focused on sequencing the genomes of cancerous cells from humans.